Patents Assigned to Genentech
  • Anti-polyubiquitin antibodies and methods of use
    Patent number: 10100105
    Abstract: The invention provides anti-polyubiquitin antibodies and methods of using the same.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: October 16, 2018
    Assignee: Genentech, Inc.
    Inventors: Vishva Dixit, Robert F. Kelley, Marissa L. Matsumoto
  • Compositions and methods for regulating cell osmolarity
    Patent number: 10100319
    Abstract: The invention provides compositions and methods for regulating intracellular osmolarity in cells, e.g., in cultured cells, including in cultured cells in bioreactors. The invention provides nucleic acids comprising at least one osmo-responsive transcriptional regulatory element (OR-TRE), and cells, vectors, products of manufacture, artificial organs or implants and the like containing an osmo-responsive transcriptional regulatory element (OR-TRE).
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: October 16, 2018
    Assignee: GENENTECH, INC.
    Inventors: Laetitia Malphettes, Andrew Snowden, Inn H. Yuk
  • METHODS AND COMPOSITIONS COMPRISING PURIFIED RECOMBINANT POLYPEPTIDES
    Publication number: 20180291094
    Abstract: Purified recombinant polypeptides isolated from Chinese hamster ovary host cells, including antibodies, such as therapeutic antibodies, and methods of making and using such polypeptides are provided.
    Type: Application
    Filed: February 22, 2018
    Publication date: October 11, 2018
    Applicant: Genentech, Inc.
    Inventors: X. Christopher Yu, Susan C. Fisher, Ailen M. Sanchez, Martin Vanderlaan
  • ANTAGONIST ANTI-NOTCH3 ANTIBODIES AND THEIR USE IN THE PREVENTION AND TREATMENT OF NOTCH3-RELATED DISEASES
    Publication number: 20180291090
    Abstract: The present invention relates to antagonist antibodies that specifically bind to Notch 3 and inhibit its activation. The present invention includes antibodies binding to a conformational epitope comprising the first Lin12 domain and the second dimerization domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.
    Type: Application
    Filed: December 15, 2017
    Publication date: October 11, 2018
    Applicant: GENENTECH, INC.
    Inventors: Sek Chung Fung, Kang Li, Yucheng Li, Sanjaya Singh, Bin-Bing Stephen Zhou
  • HUMANIZED ANTI-BETA7 ANTAGONISTS AND USES THEREFOR
    Publication number: 20180291104
    Abstract: The invention provides therapeutic anti-beta7 antibodies, compositions comprising, and methods of using these antibodies.
    Type: Application
    Filed: September 29, 2017
    Publication date: October 11, 2018
    Applicant: Genentech, Inc.
    Inventors: Sherman Fong, Mark Dennis
  • METHODS AND COMPOSITIONS COMPRISING PURIFIED RECOMBINANT POLYPEPTIDES
    Publication number: 20180291095
    Abstract: Purified recombinant polypeptides isolated from Chinese hamster ovary host cells, including antibodies, such as therapeutic antibodies, and methods of making and using such polypeptides are provided.
    Type: Application
    Filed: February 22, 2018
    Publication date: October 11, 2018
    Applicant: Genentech, Inc.
    Inventors: X. Christopher Yu, Saloumeh Kadkhodayan Fischer, Susan C. Fisher, John Lowe, Atia Naim, Ailen M. Sanchez, Christopher A. Teske, Martin Vanderlaan, Annamarie Amurao, Jayme Franklin, Corazon Victa
  • THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20180291014
    Abstract: The invention provides a compound of formula: or a salt thereof, wherein the variables RAA, n, ring A, ring B, R1a, R1b, R2, R3, R4, R5, R6, R7, R8, and R9 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: March 28, 2018
    Publication date: October 11, 2018
    Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Phillipe BERGERON, Kristen BURFORD, Sultan CHOWDHURY, Christoph Martin DEHNHARDT, Thilo FOCKEN, Michael Edward GRIMWOOD, Abid HASAN, Kwong Wah LAI, Zhiguo LIU, Steven MCKERRALL, Teresa Phuongtram NGUYEN, Brian SAFINA, Daniel SUTHERLIN, Tao WANG
  • USP30 INHIBITORS AND METHODS OF USE
    Publication number: 20180291380
    Abstract: Inhibitors of USP30 and methods of using inhibitors of USP30 are provided. In some embodiments, methods of treating conditions involving mitochondrial defects are provided.
    Type: Application
    Filed: February 23, 2018
    Publication date: October 11, 2018
    Applicant: Genentech, Inc.
    Inventors: Yingnan Zhang, Baris Bingol Bingol, Jacob Corn
  • Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use
    Patent number: 10092567
    Abstract: The invention provides combinations comprising a) compound of formula I: or a pharmaceutically acceptable salt thereof wherein R1, R2, R5, R10, and A have any of the values defined in the specification; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: October 9, 2018
    Assignee: GENENTECH, INC.
    Inventors: Kui Lin, Michelle Nannini, Elizabeth Punnoose, Deepak Sampath, Jeffrey Wallin, Premal Patel
  • Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms
    Patent number: 10093978
    Abstract: The invention provides methods and compositions for treating various degenerative diseases (e.g., AMD) with a factor D inhibitor (e.g., anti-factor D antibody or antigen-binding fragment thereof). Also provided are methods of selecting or identifying patients for treatment with a factor D inhibitor. Methods include the use of prognostic and/or predictive biomarkers.
    Type: Grant
    Filed: August 11, 2014
    Date of Patent: October 9, 2018
    Assignee: GENENTECH, INC.
    Inventors: Brian Yaspan, Robert Royal Graham, Amy Dressen, Zhengrong Li, Erich Strauss, Teodorica Bugawan
  • Anti-interleukin-33 antibodies and uses thereof
    Patent number: 10093730
    Abstract: The invention provides interleukin-33 (IL-33) antibodies and methods of using the same.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: October 9, 2018
    Assignee: Genentech, Inc.
    Inventors: Philip E. Hass, Meredith Hazen, Yi-Chun Hsiao, Rajita Khosla, Gerald R. Nakamura, Dhaya Seshasayee, Menno Van Lookeren Campagne, Hongkang Xi, Wenwu Zhai, Jack Bevers, III, Nancy Chiang
  • CRYSTALLINE FORMS OF A PYRROLOPYRIDINE COMPOUND
    Publication number: 20180282324
    Abstract: Disclosed are crystalline forms of (R)—N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)cyclopropanecarboxamide, and salts, solvates, and hydrates thereof, and pharmaceutical compositions, formulations and a process of manufacturing thereof.
    Type: Application
    Filed: November 8, 2017
    Publication date: October 4, 2018
    Applicants: Genentech, Inc., Array Biopharma Inc.
    Inventors: Jeffrey Stults, Christopher M. Lindemann, Keith L. Spencer, Weidong Liu, Joseph Lubach
  • MUTANT SELECTIVITY AND COMBINATIONS OF A PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUND AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER
    Publication number: 20180280408
    Abstract: Methods and compositions are provided for treating hyperproliferative disorders in patients with a PI3K inhibitor, GDC-0032 as a single agent or in combination with chemotherapeutic agents.
    Type: Application
    Filed: February 14, 2018
    Publication date: October 4, 2018
    Applicant: Genentech, Inc.
    Inventors: Marcia Belvin, Lori Friedman, Deepak Sampath, Jeffrey Wallin
  • NAPHTHYRIDINES AS INHIBITORS OF HPK1
    Publication number: 20180282328
    Abstract: Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.
    Type: Application
    Filed: March 30, 2018
    Publication date: October 4, 2018
    Applicant: Genentech, Inc.
    Inventors: Bryan Chan, Blake Daniels, Joy Drobnick, Lewis Gazzard, Timothy Heffron, Malcolm Huestis, Jun Liang, Sushant Malhotra, Rohan Mendonca, Naomi Rajapaksa, Michael Siu, Craig Stivala, John Tellis, Weiru Wang, BinQing Wei, Aihe Zhou, Matthew W. Cartwright, Emanuela Gancia, Graham Jones, Michael Lainchbury, Andrew Madin, Eileen Seward, David Favor, Kin Chiu Fong, Andrew Good, Yonghan Hu, Baihua Hu, Aijun Lu
  • ISOQUINOLINES AS INHIBITORS OF HPK1
    Publication number: 20180282282
    Abstract: Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibitng HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.
    Type: Application
    Filed: March 30, 2018
    Publication date: October 4, 2018
    Applicant: Genentech, Inc.
    Inventors: Bryan Chan, Joy Drobnick, Lewis Gazzard, Timothy Heffron, Jun Liang, Sushant Malhotra, Rohan Mendonca, Naomi Rajapaksa, Craig Stivala, John Tellis, Weiru Wang, BinQing Wei, Aihe Zhou, Matthew W. Cartwright, Michael Lainchbury, Emanuela Gancia, Eileen Seward, Andrew Madin, David Favor, Kin Chiu Fong, Yonghan Hu, Andrew Good
  • ANTI-ErbB2 ANTIBODIES
    Publication number: 20180282428
    Abstract: Anti-ErbB2 antibodies are described which bind to an epitope in Domain 1 of ErbB2 and induce cell death via apoptosis. Various uses for these antibodies are also described.
    Type: Application
    Filed: June 15, 2018
    Publication date: October 4, 2018
    Applicant: Genentech, Inc.
    Inventors: Brian M. Fendly, Gail Dianne Phillips, Richard Scheuermann, Jonathan W. Uhr
  • METHODS AND COMPOSITIONS FOR TREATING CANCER USING PD-1 AXIS ANTAGONISTS AND HPK1 ANTAGONISTS
    Publication number: 20180280505
    Abstract: Compositions and methods for enhancing an immune response and treating cancer are provided. Compositions comprise PD-1 axis antagonists and HPK1 antagonists. PD-1 axis antagonists include PD-1 antagonists, PD-L1 antagonists, and PD-L2 antagonists. PD-1 axis antagonists can inhibit the binding of PD-L1 and/or PD-L2 to PD-1. HPK1 antagonists include compounds that inhibit the serine/threonine kinase activity of HPK1. Methods for enhancing an immune response or treating cancer comprise administering a PD-1 axis antagonist and a HPK1 antagonist, sequentially or simultaneously, to a subject in need thereof.
    Type: Application
    Filed: January 31, 2018
    Publication date: October 4, 2018
    Applicant: Genentech, Inc.
    Inventors: Sairy Hernandez, Ira Mellman, Jing Qing, Deepak Sampath
  • SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS
    Publication number: 20180282272
    Abstract: The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Application
    Filed: June 6, 2018
    Publication date: October 4, 2018
    Applicant: Genentech, Inc.
    Inventors: Huifen CHEN, Yanyan CHU, Steven DO, Anthony ESTRADA, Baihua HU, Aleksandr KOLESNIKOV, Xingyu LIN, Joseph P. LYSSIKATOS, Daniel SHORE, Vishal VERMA, Lan WANG, Guosheng WU, Po-wai YUEN
  • Nucleic acids encoding IL-22 Fc fusion proteins
    Patent number: 10087227
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: October 2, 2018
    Assignee: Genentech, Inc.
    Inventors: Justin Scheer, Wenjun Ouyang, Richard Vandlen, Philip E. Hass, Eric Gary Stefanich, Xiaoting Wang
  • METHODS AND COMPOSITIONS COMPRISING PURIFIED RECOMBINANT POLYPEPTIDES
    Publication number: 20180273615
    Abstract: Purified recombinant polypeptides isolated from Chinese hamster ovary host cells, including antibodies, such as therapeutic antibodies, and methods of making and using such polypeptides are provided.
    Type: Application
    Filed: February 1, 2018
    Publication date: September 27, 2018
    Applicant: Genentech, Inc.
    Inventors: X. Christopher Yu, Saloumeh Kadkhodayan Fischer, Susan C. Fisher, John Lowe, Ailen M. Sanchez, Martin Vanderlaan